ROCKVILLE, MD, Dec. 18, 2020 (GLOBE NEWSWIRE) —
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc. The research collaboration will incorporate MacroGenics’ proprietary DART® platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology.
{iframe}https://www.macrogenics.com/news/macrogenics-enters-research-collaboration-with-janssen-to-develop-novel-dart-molecule/{/iframe}